title: Treatment of chronic hepatitis C: comparative virologic response rates among the different interferons.
abstract: End-treatment and sustained virologic response rates are similar in large, comparative controlled trials which have compared the standard dosing regimens of interferon alpha-2b to interferon alpha-nl and consensus interferon, as well as to virologic response rates recently reported with interferon alpha-2b monotherapy for 24 weeks. For patients who have responded and relapsed after an initial course of alpha interferon, retreatment with consensus interferon for 48 weeks demonstrates a high sustained virologic response rate, similar to that reported with interferon alpha-2b combined with ribavirin for 24 weeks. Based on available pharmacokinetic and pharmacodynamic data, pegylation of interferon alpha-2a shows promise in demonstrating high sustained serum levels and 2',5' OAS activity. Preliminary data from a Phase II clinical trial of a 48-week treatment in naive patients demonstrates end-treatment and sustained virologic response rates similar to that seen with interferon alpha-2b combined with ribavirin for 48 weeks.
authors.affiliation: Division of Gastrointestinal and Liver Disease, University of Southern California, Los Angeles 90033, USA. klindsay@hsc.usc.edu
authors.forename: K L
authors.initials: KL
authors.lastname: Lindsay
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D007370:Interferon Type I / Q000627:therapeutic use*; D016898:Interferon-alpha / Q000627:therapeutic use*; D011994:Recombinant Proteins
chemical_list: D000998:Antiviral Agents; D007370:Interferon Type I; D016898:Interferon-alpha; D011994:Recombinant Proteins; C050739:interferon alfacon-1